(NASDAQ: GLYC) Glycomimetics's forecast annual revenue growth rate of 1,773.37% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.8%.
Glycomimetics's revenue in 2024 is $10,000.On average, 2 Wall Street analysts forecast GLYC's revenue for 2025 to be $1,817,178,605, with the lowest GLYC revenue forecast at $688,974,616, and the highest GLYC revenue forecast at $2,945,382,595. On average, 2 Wall Street analysts forecast GLYC's revenue for 2026 to be $4,644,939,247, with the lowest GLYC revenue forecast at $3,689,784,541, and the highest GLYC revenue forecast at $5,600,093,953.
In 2027, GLYC is forecast to generate $8,787,165,491 in revenue, with the lowest revenue forecast at $8,787,165,491 and the highest revenue forecast at $8,787,165,491.